Nikolaus Schultz Selected Research

Melanoma (Melanoma, Malignant)

1/2023	Undifferentiated and Dedifferentiated Metastatic Melanomas Masquerading as Soft Tissue Sarcomas: Mutational Signature Analysis and Immunotherapy Response.
1/2021	Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas.
4/2014	Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nikolaus Schultz Research Topics

Disease

135	Neoplasms (Cancer) 05/2024 - 06/2009
24	Prostatic Neoplasms (Prostate Cancer) 05/2024 - 07/2010
15	Neoplasm Metastasis (Metastasis) 03/2024 - 04/2014
9	Colorectal Neoplasms (Colorectal Cancer) 03/2024 - 01/2013
9	Adenocarcinoma 01/2023 - 01/2016
8	Breast Neoplasms (Breast Cancer) 01/2021 - 08/2011
7	Carcinoma (Carcinomatosis) 01/2021 - 01/2012
6	Microsatellite Instability 01/2023 - 01/2013
6	Ovarian Neoplasms (Ovarian Cancer) 01/2021 - 01/2012
6	Glioma (Gliomas) 01/2019 - 01/2012
6	Glioblastoma (Glioblastoma Multiforme) 10/2015 - 06/2009
5	Urinary Bladder Neoplasms (Bladder Cancer) 04/2024 - 01/2017
5	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2023 - 01/2018
5	Carcinogenesis 12/2017 - 06/2009
4	Circulating Neoplastic Cells 03/2024 - 12/2012
4	Stomach Neoplasms (Stomach Cancer) 01/2023 - 01/2019
4	Genomic Instability 01/2023 - 10/2013
4	Adenocarcinoma of Lung 01/2021 - 08/2015
3	Pancreatic Neoplasms (Pancreatic Cancer) 05/2024 - 10/2017
3	Brain Neoplasms (Brain Tumor) 01/2023 - 01/2012
3	Melanoma (Melanoma, Malignant) 01/2023 - 04/2014
3	Renal Cell Carcinoma (Grawitz Tumor) 01/2022 - 04/2014
3	Cholangiocarcinoma 01/2022 - 01/2018
2	Prostatic Intraepithelial Neoplasia 01/2023 - 01/2023
2	Sarcoma (Soft Tissue Sarcoma) 01/2023 - 01/2019
2	Rectal Neoplasms (Rectal Cancer) 01/2022 - 01/2020
2	Kidney Neoplasms (Kidney Cancer) 01/2022 - 04/2014
2	Lung Neoplasms (Lung Cancer) 01/2021 - 01/2019
2	Disease Progression 01/2020 - 01/2019
2	Synovial Sarcoma (Synovioma) 12/2018 - 01/2018
2	Oligodendroglioma 10/2017 - 09/2014
1	Aneuploidy (Aneuploid) 10/2023

Drug/Important Bio-Agent (IBA)

25	DNA (Deoxyribonucleic Acid)IBA 08/2022 - 07/2010
20	Proteins (Proteins, Gene)FDA Link 08/2022 - 01/2010
19	Biomarkers (Surrogate Marker)IBA 10/2023 - 06/2014
13	RNA (Ribonucleic Acid)IBA 03/2024 - 08/2011
11	GenieIBA 05/2024 - 12/2018
8	Cisplatin (Platino)FDA LinkGeneric 04/2024 - 01/2016
8	Phosphotransferases (Kinase)IBA 03/2024 - 06/2009
8	Immune Checkpoint InhibitorsIBA 10/2022 - 01/2018
8	Messenger RNA (mRNA)IBA 01/2022 - 07/2010
7	Trastuzumab (Herceptin)FDA Link 01/2023 - 04/2015
7	EnzymesIBA 01/2022 - 12/2012
5	MicroRNAs (MicroRNA)IBA 01/2019 - 01/2012
4	pembrolizumabIBA 01/2023 - 04/2019
4	Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA 01/2021 - 08/2011
4	PlatinumIBA 01/2020 - 01/2017
4	Estrogen ReceptorsIBA 01/2020 - 01/2018
4	ChromatinIBA 01/2019 - 07/2013
4	AndrogensIBA 01/2018 - 07/2010
3	Gemcitabine FDA Link 04/2024 - 01/2020
3	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 07/2023 - 04/2014
3	NucleotidesIBA 01/2022 - 11/2014
3	Prostate-Specific Antigen (Semenogelase)IBA 01/2022 - 07/2014
3	Calcibiotic Root Canal SealerIBA 11/2021 - 01/2013
3	Cyclin-Dependent Kinase Inhibitor p16IBA 01/2021 - 06/2014
3	Fluorouracil (Carac)FDA LinkGeneric 01/2020 - 01/2019
3	Oncogene Proteins (Oncogene Protein)IBA 12/2018 - 01/2012
3	Hormones (Hormone)IBA 10/2018 - 05/2016
2	Complement System Proteins (Complement)IBA 05/2024 - 01/2020
2	tyrosine receptor (receptor, tyrosine)IBA 03/2024 - 01/2022
2	Circulating Tumor DNAIBA 01/2023 - 11/2022
2	Tyrosine Kinase InhibitorsIBA 01/2023 - 01/2019
2	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 08/2011
2	ErbB Receptors (EGF Receptor)IBA 01/2022 - 04/2015
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2021 - 01/2019
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2020 - 01/2020
2	Androgen Receptors (Androgen Receptor)IBA 01/2020 - 12/2012
2	B7-H1 AntigenIBA 04/2019 - 01/2018
2	Mitochondrial DNA (mtDNA)IBA 01/2019 - 01/2017
2	MethyltransferasesIBA 12/2018 - 01/2018
2	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 01/2018 - 07/2010
2	LigandsIBA 01/2018 - 01/2018
2	Transcription Factors (Transcription Factor)IBA 01/2018 - 12/2012
2	Indicators and Reagents (Reagents)IBA 01/2017 - 09/2015
2	CytosineIBA 01/2017 - 12/2011
2	Formaldehyde (Formol)FDA Link 05/2016 - 10/2015
2	ParaffinIBA 05/2016 - 10/2015
2	Exonucleases (3' 5' Exonuclease)IBA 10/2015 - 11/2014
2	AgarIBA 01/2015 - 12/2013
2	MTOR InhibitorsIBA 04/2014 - 01/2012
2	Phosphoric Monoester Hydrolases (Phosphatases)IBA 08/2011 - 06/2009
1	Farnesyltranstransferase (Farnesyltransferase)IBA 07/2023
1	tipifarnib (R115777)IBA 07/2023
1	Cell-Free Nucleic AcidsIBA 01/2023
1	alectinibIBA 01/2023
1	zirconium-89-trastuzumabIBA 01/2023
1	Small Cytoplasmic RNAIBA 01/2023
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2023

Therapy/Procedure

56	Therapeutics 04/2024 - 12/2011
31	Drug Therapy (Chemotherapy) 04/2024 - 12/2011
11	Castration 01/2023 - 12/2012
7	Precision Medicine 05/2024 - 05/2015
7	Neoadjuvant Therapy 04/2024 - 04/2015
5	Immunotherapy 01/2023 - 12/2017
3	Cystectomy 04/2024 - 02/2015
2	Hepatectomy 11/2022 - 04/2022
2	Cytoreduction Surgical Procedures 02/2021 - 12/2020
1	Duration of Therapy 03/2024
1	Adjuvant Chemotherapy 01/2023